Speakers 2024

Speakers 2024



Chief medical officer

Jens Hasskarl is the chief medical officer of advesya, a French startup focused on developing lifesaving therapies. Prior to joining advesya, he was the chief medical officer of Tigen Pharma SA, a Swiss startup developing cellular therapies to fight solid tumors. Before that he was working as Clinical Program Lead physician in the cell therapies program at Celgene. As head Europe of the Cellular Therapy Clinical Center of Excellence he was instrumentally involved in the development of liso-cel (Breyanzi® and ide-cel (Abecma®). Prior to joining Celgene, Jens served in various global roles with ascending responsibilities at Novartis and iOMEDICO, beginning in 2009. In these roles he was responsible for developing and successfully executing the development strategy across various compounds. He was the Global Lead on the Novartis CAR T CTL-019 program for NHL, and the lead CRP on the JULIET trial, which lead to approval of CTL019 (Kymriah®) in DLBCL. Jens received his medical education at Freiburg Medical School, University of Vienna Medical School, University of Heidelberg Medical School and Harvard Medical School. He completed his thesis in cancer biology at the German Cancer Research Center in Heidelberg and at Harvard Medical School. He received his medical training - interrupted by 3 years postdoc at Harvard Medical School - at the University of Freiburg as board certified hematologist and oncologist. Jens is a member of the medical faculty in Freiburg and continues to lecture there.

Find also